EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The apoptotic and anti‐proliferative effects of Neosetophomone B in T‐cell acute lymphoblastic leukaemia via PI3K / AKT / mTOR pathway inhibition

Shilpa Kuttikrishnan, Abdul W Ansari, Muhammad Suleman, Fareed Ahmad, Kirti S Prabhu, Tamam El-Elimat, Feras Q Alali, Ammira S Al Shabeeb Akil, Ajaz A Bhat, Maysaloun Merhi, Said Dermime, Martin Steinhoff und 1 weitere

Cell Proliferation · 2025

DOI: 10.1111/cpr.13773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Proliferation, 2025. Verfasst von Shilpa Kuttikrishnan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: Apoptosis, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Signal Transduction. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hamad Medical Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phosphatidylinositol 3‐kinase/Protein Kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signalling pathway is pivotal in various cancers, including T‐cell acute lymphoblastic leukaemia (T‐ALL), a particularly aggressive type of leukaemia. This study investigates the effects of Neosetophomone B (NSP‐B), a meroterpenoid fungal metabolite, on T‐ALL cell lines, focusing on its anti‐cancer mechanisms and therapeutic potential. NSP‐B significantly inhibited the proliferation of T‐ALL cells by inducing G0/G1 cell cycle arrest and promoting caspase‐dependent apoptosis. Additionally, NSP‐B led to the dephosphorylation and subsequent inactivation of the PI3K/AKT/mTOR signalling pathway, a critical pathway in cell survival and growth. Molecular docking studies revealed a strong binding affinity of NSP‐B to the active site of AKT, primarily involving key residues crucial for its activity. Interestingly, NSP‐B treatment also induced apoptosis and significantly reduced proliferation in phytohemagglutinin‐activated primary human CD3 + T cells, accompanied by a G0/G1 cell cycle arrest. Importantly, NSP‐B did not affect normal primary T cells, indicating a degree of selectivity in its action, targeting only T‐ALL cells and activated T cells. In conclusion, our findings highlight the potential of NSP‐B as a novel therapeutic agent for T‐ALL, specifically targeting the aberrantly activated PI3K/AKT/mTOR pathway and being selective in action. These results provide a strong basis for further investigation into NSP‐B's anti‐cancer properties and potential application in T‐ALL clinical therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ApoptosisTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktSignal TransductionPrecursor T-Cell Lymphoblastic Leukemia-LymphomaAntineoplastic AgentsHumansCell ProliferationPhosphatidylinositol 3-KinasesMolecular Docking SimulationCell Line, TumorTerpenes

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMTOR protein, humanAntineoplastic Agentsneosetophomone BTerpenes

Autor:innen und Institutionen

  • Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
  • Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.
  • Laboratory of Animal Research Center, Qatar University, Doha, Qatar.
  • Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Qatar.
  • Department of Human Genetics-Precision Medicine in Diabetes, Obesity and Cancer Program, Sidra Medicine, Doha, Qatar.

ORCID-Profile: Shahab Uddin

Förderung

  • Hamad Medical Corporation

Zitieren

APA

Kuttikrishnan, S., Ansari, A. W., Suleman, M., Ahmad, F., Prabhu, K. S., El-Elimat, T., Alali, F. Q., Al Shabeeb Akil, A. S., Bhat, A. A., Merhi, M., Dermime, S., Steinhoff, M., & Uddin, S. (2025). The apoptotic and anti‐proliferative effects of Neosetophomone B in T‐cell acute lymphoblastic leukaemia via PI3K / AKT / mTOR pathway inhibition. Cell Proliferation. https://doi.org/10.1111/cpr.13773

Vancouver

Kuttikrishnan S, Ansari AW, Suleman M, Ahmad F, Prabhu KS, El-Elimat T, et al. The apoptotic and anti‐proliferative effects of Neosetophomone B in T‐cell acute lymphoblastic leukaemia via PI3K / AKT / mTOR pathway inhibition. Cell Proliferation. 2025. doi:10.1111/cpr.13773

BibTeX
@article{Kuttikrishnan2025,
  author = {Kuttikrishnan, Shilpa and Ansari, Abdul W and Suleman, Muhammad and Ahmad, Fareed and Prabhu, Kirti S and El-Elimat, Tamam and Alali, Feras Q and Al Shabeeb Akil, Ammira S and Bhat, Ajaz A and Merhi, Maysaloun and Dermime, Said and Steinhoff, Martin and Uddin, Shahab},
  title = {The apoptotic and anti‐proliferative effects of Neosetophomone B in T‐cell acute lymphoblastic leukaemia via PI3K / AKT / mTOR pathway inhibition},
  journal = {Cell Proliferation},
  year = {2025},
  doi = {10.1111/cpr.13773}
}
Kostenlos starten →